Key Takeaways
-
Wegovy (semaglutide) is TGA-approved in Australia for chronic weight management and to reduce cardiovascular risk in adults with existing heart disease.
-
It works by mimicking the GLP-1 hormone, reducing appetite and slowing stomach emptying.
-
Dosing starts at 0.25 mg weekly and is gradually increased to a maintenance dose of 2.4 mg weekly over 16 weeks.
-
Common side effects are gastrointestinal (nausea, vomiting, diarrhea, constipation); serious risks include pancreatitis, gallbladder disease, and possible thyroid tumors.
-
Wegovy is not PBS-subsidised for weight management, so cost is a major access barrier for patients.
-
Weight regain is common after stopping treatment, so long-term use alongside lifestyle changes is usually needed.
Wegovy has become one of the most talked-about medicines in Australian pharmacy since its launch in August 2024. As demand for GLP-1 medicines continues to grow, pharmacists are increasingly the first point of contact for patient questions about eligibility, dosing, safety, and cost. This guide breaks down the essential facts about Wegovy in a simple, practical format, covering how it works, who it's for, and what to flag during counselling.
1. What Is Wegovy?
Wegovy is a prescription injectable medicine containing semaglutide, used for weight management and cardiovascular risk reduction.
-
Approved for adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with a weight-related health condition
-
Also approved for adolescents aged 12+ with obesity and body weight over 60 kg
-
Approved to reduce the risk of major cardiovascular events (death, heart attack, stroke) in adults with existing heart disease and a BMI ≥27 kg/m²
-
Must always be used alongside a reduced-calorie diet and increased physical activity
-
Should never be combined with other semaglutide products or other GLP-1 receptor agonists (e.g., liraglutide, dulaglutide, exenatide, lixisenatide)
2. How Does Wegovy Work?
Wegovy works by mimicking the natural hormone GLP-1 to reduce appetite and slow digestion.
-
Acts on brain receptors that control hunger, increasing feelings of fullness
-
Slows gastric emptying, prolonging satiety after meals
-
Stimulates insulin release and reduces glucagon secretion
-
These combined effects reduce food intake and support gradual weight loss
3. Who Can Use Wegovy in Australia?
Wegovy is suitable for specific adult and adolescent populations meeting BMI and health criteria.
Wegovy should not be used in patients who:
-
Have a personal or family history of medullary thyroid carcinoma (MTC)
-
Have Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2)
-
Have had a serious allergic reaction to semaglutide or its ingredients
-
Have type 1 diabetes (not recommended)
4. What Is the Correct Dosing Schedule?
Wegovy dosing starts low and is gradually titrated up over 16 weeks to the 2.4 mg maintenance dose.
-
Given once weekly, on the same day each week where possible
-
Dosing day can be changed if at least 3 days have passed since the last injection
-
If a dose is missed and it's been 5 days or less, administer as soon as remembered
-
If more than 5 days have passed, skip the missed dose entirely, never double up
5. How Should Wegovy Be Stored and Administered?
Wegovy must be refrigerated when not in use and administered as a subcutaneous injection only.
-
Store in the fridge (2°C–8°C); do not freeze
-
Can be kept at room temperature (below 30°C) for up to 6 weeks once removed from the fridge
-
Inject under the skin in the upper arm, thigh, or stomach, never into a vein or muscle
-
Each pen should be discarded after 6 weeks, even if some solution remains
-
Never share the pen with anyone else, even with a changed needle
6. What Are the Common Side Effects?
Most Wegovy side effects are gastrointestinal and tend to improve over time.
-
Nausea, vomiting, and diarrhea
-
Constipation and stomach pain
-
Headache and fatigue
-
Bloating, gas, and burping
-
Reflux or heartburn
-
Dizziness
-
Hair loss
-
Low blood sugar (mainly in patients also using insulin or sulfonylureas)
Advise patients to stay well hydrated, especially if experiencing vomiting or diarrhea, to reduce the risk of dehydration and kidney complications.
7. What Are the Serious Risks Pharmacists Should Watch For?
Wegovy carries several serious but less common risks that require prompt medical attention.
-
Pancreatitis: severe, persistent abdominal pain, sometimes radiating to the back
-
Gallbladder problems: including gallstones, which may need surgery
-
Thyroid tumors: seen in animal studies; not confirmed in humans, but a boxed warning applies
-
Severe allergic reactions: facial/throat swelling, breathing difficulty, rapid heartbeat
-
Diabetic retinopathy complications: in patients with type 2 diabetes
-
Aspiration risk during anesthesia: due to delayed stomach emptying; patients should inform all care providers before any procedure requiring sedation
Pharmacists should also monitor for mental health changes, as GLP-1 medicines can affect a patient's relationship with food and, in rare cases, mood.
8. How Does Wegovy Compare to Other Weight-Loss Injectables?
Semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide differ in dosing frequency and average weight loss outcomes.
-
Wegovy's weekly dosing is often preferred by patients over Saxenda's daily injections
-
Tirzepatide has shown higher average weight loss in some trials but is a separate class of medicine
-
None of these medicines are currently PBS-subsidised for weight management in Australia
9. What Should Patients Know Before Starting Wegovy?
Patients need realistic expectations, as Wegovy is generally intended for long-term use.
-
Weight regain is common if the medicine is stopped, studies show a large proportion of lost weight returns within 12 months
-
Wegovy works best combined with dietitian support, exercise guidance, and regular GP follow-up
-
It is not a substitute for insulin in patients with diabetes
-
Should be stopped at least 2 months before a planned pregnancy
-
Not recommended during breastfeeding
-
Patients travelling should carry a letter from their doctor explaining their injectable device
Conclusion
Wegovy has given Australian pharmacists another practical tool for supporting patients with weight management and cardiovascular risk reduction. But as with all GLP-1 medicines, it works best as part of a bigger picture, not a quick fix. Pharmacists play a key role in guiding patients through dose titration, spotting early warning signs of serious side effects, and setting realistic expectations around long-term use and weight regain.
With cost remaining a major barrier and demand continuing to rise, clear, simple counselling at the pharmacy counter can make a real difference in how safely and effectively patients use this medicine. Staying up-to-date with TGA guidance and manufacturer safety information will help pharmacists continue to support patients confidently as Wegovy becomes a more common part of everyday practice
Start Your Australian Pharmacy Journey Today
Whether you're preparing for the OPRA Exam or planning your pharmacy career in Australia, Elite Expertise provides expert guidance, structured study programs, and one-to-one mentoring to help you succeed with confidence.
Contact Us TodayReferences
Explore the official resources used to prepare this guide.
Wegovy Official Guide
Official prescribing information, dosing schedule, storage instructions and patient guidance.
Visit Website →Medicine Finder
Australian medicine information, safety advice, approved indications and product details.
Read More →Australian Pharmacist
Expert insights into Wegovy, obesity management and the evolving role of pharmacists.
Explore →Australian Prescriber
Evidence-based clinical guidance on injectable medicines used for weight management.
View Article →